Cannabis play RotoGro wraps up $4.5M raising
Roto-Gro International Limited (ASX:RGI) is pleased to announce it has completed the final tranche of the $4.56 million capital raising to institutional and sophisticated investors announced on 20 June 2018.
The high demand capital raise, jointly managed by Barclay Wells Limited Pty Ltd and Emerald Capital Australia Pty Ltd, will allow RGI to fast-track the pursuit of strategic acquisitions in lawful cannabis licenses, nutrients and perishable foods by way of equity ownership or partnership.
The company is presently focussed on expanding the research and development facility in Caledon, Ontario, Canada, as well as bolstering its sales and management teams.
The final tranche of 5,418,698 shares completes a total of 12,000,000 new fully paid ordinary shares issued at $0.38 per share.
The company will also seek shareholder approval for the issue of 8,800,000 new unlisted options, exercisable at $0.65 and expiring two years from date of issue.
RGI updates on recent promising developments
Production continues for the Miracle Valley Medicinal Alternatives M.V.M.A. Ltd’s $2.3 million purchase order for the manufacture of RotoGro Rotational Hydroponic Gardens for their 29,000 square feet ‘state of the art’ cultivation and manufacturing facility in British Columbia, Canada.
RGI are now required to wait until end of October to access the site, in order to undertake RotoGro Installation. Meanwhile, the company has been working with Miracle Valley to finalise the design of a fertigation system for their expanded facility.
The small cap is currently designing Gibio’s first flagship facility to incorporated automated unloading, washing, harvesting and packing of their Perishable crops. The 8’ Prototype Rotational Gardens are nearly complete with weekly collaboration between RotoGro and Gibio to continually refine the feeding and harvesting aspects of the Units.
Freshero has a dedicated Grow Room at RGI’s Ontario facility. In mid-September, key members of Freshero’s management visited RGI’s Ontario and Nevada facilities, however the company has shortened and delayed the start of their trials, which are now set to commence mid-October.
It’s worth noting here that this is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.
RGI considers complementary acquisitions
As previously flagged by the company, it continues a focus on expanding into industry synergistic opportunities, including exploring strategic partnerships and complimentary acquisitions in related markets.
These markets include lawful cannabis license ownership, growing management services, industry leading nutrients, emerging tissue culture expertise and other supporting faculties of hydroponic growing.
RGI is now assessing opportunities to acquire a Cannabis Cultivation License in Canada and is consequently in discussions with a number of license holders. At this stage, all discussions are preliminary.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.